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Coordination of events leading to differentiation is
mediated by the concerted action of multiple signal
transduction pathways. In general, the uncoupling of
mechanisms linking differentiation to cell cycle exit is
a hallmark of cancer, yet the identity and regulation
of molecules integrating signal transduction path-
ways remains largely unknown. One notable excep-
tion is DARPP-32 (dopamine and cAMP-regulated
neuronal phosphoprotein, molecular mass, 32 kDa),
a third messenger that integrates multiple signaling
pathways in the brain. Thyroid cells represent an
excellent model for understanding the coupling of
signal transduction pathways leading to both prolif-
eration and differentiation. The cooperative action of
IGF-I and TSH together, but not alone, enable thyroid
cells to proliferate while maintaining their differenti-
ated state. How signaling downstream from these
molecules is integrated is not known. Here we show
that DARPP-32 expression is targeted by TSH and
IGF-I in thyrocytes. Significantly, dedifferentiated, tu-
moral, or Ras-transformed thyrocytes fail to express
DARPP-32 whereas short interfering RNA-mediated
silencing of DARPP-32 expression in normally differ-
entiated thyroid cells results in loss of differentiation
markers such as thyroid transcription factor 1, Pax8,
thyroglobulin, and the Na/I symporter. Consistently,
DARPP-32 reexpression in ras-transformed cells re-
sults in reactivation of the otherwise silent thyroglob-
ulin and thyroperoxidase promoter. Thus, DARPP-32
is critical for the maintenance of thyroid differentia-
tion by TSH and IGF-I, and loss of DARPP-32 expres-
sion may be a characteristic of thyroid cancer. Our
results also raise the possibility that DARPP-32 may
play a similar role in the maintenance of differentia-
tion of a range of other cell types. (Molecular Endo-
crinology 19: 3060–3072, 2005)
CELL DIFFERENTIATION OCCURS as a result ofthe concerted activation of multiple signaling
pathways in response to environmental stimuli. In
general, differentiation occurs at the expense of pro-
liferation and, as such, signaling pathways regulat-
ing proliferation must be coordinated with those
promoting differentiation. Thyroid cells represent an
excellent system because the main stimuli govern-
ing their function cooperatively promote both
growth and differentiation. Differentiated thyroid
cells express a number of final differentiation mark-
ers such as thyroglobulin (Tg), thyroperoxidase
(TPO) and the Na/I symporter (NIS) the expression of
which is governed by combinations of ubiquitous
and thyroid-specific transcription factors such as
thyroid-specific transcription factor (TTF)1, TTF2,
and Pax8 (1). Differentiated thyroid cells in culture
are dependent on the presence of TSH and insulin/
IGF-I, which cooperate to promote both growth and
differentiation (2, 3). Undifferentiated thyrocytes can
also be maintained in culture in a medium depleted
of serum, TSH, and IGF-I. Although cooperation of
both TSH and IGF-I is required for correct thyrocyte
function, the molecular mechanisms leading from
the TSH and IGF-I membrane receptors to thyroid-
specific transcription factors and consequent ex-
pression of final differentiation markers are not well
understood. TSH binds its G protein-coupled recep-
tor producing an increase in intracellular cAMP,
which activates protein kinase A (PKA), and other
pathways such as phosphatidylinositol 3-kinase
(PI3K). IGF-I, through its tyrosine kinase receptor,
activates both the PI3K and protein kinase C path-
ways. Additionally, there are indications suggesting
that a convergence from both the TSH- and IGF-I
signaling pathways might exist in the thyrocyte (4).
Given the importance of IGF-I and TSH signaling
for thyroid cell function, a major question concerns
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the identity of the molecules that play a key role in
facilitating their cooperative action. Such mediators
are important as messengers of hormone action, as
signal integrators, and as therapeutic targets. An
example of such “messengers or integrators” is pro-
vided by DARPP-32 (dopamine and cAMP-regulated
neuronal phosphoprotein; molecular mass, 32 kDa)
a molecule the expression of which was once
thought to be restricted to dopaminoceptive neu-
rons in specific brain areas where it acts as a mo-
lecular switch integrating signals from different
membrane receptors. At least 10 signaling pathways
are known to alter DARPP-32 function in the me-
dium spiny neurons of the striatum (5) where its
function and regulation have been well studied. Fur-
thermore, diverse electrophysiological and bio-
chemical alterations, as well as interesting behav-
ioral peculiarities, which characterize DARPP-32
knockout mice, reflecting the importance of the pro-
tein (6). Thus, DARPP-32 is the only known molecule
capable of alternatively inhibiting either protein
phosphatase 1 (PP1) or PKA, both of which play
crucial roles in most cell types.
Here we show that DARPP-32 is expressed in thy-
rocytes, its levels correlate with the degree of differ-
entiation, and its expression is abolished with trans-
formation. Importantly, silencing of DARPP-32 using
short interfering RNA (siRNA) results in lost of the
thyroid-specific differentiation markers and conversely
DARPP-32 reexpression in Ras-transformed cells re-
sults in reactivation of the otherwise silent Tg and TPO
promoters. Our results identify DARPP-32 as a critical
factor for thyroid differentiation promoted by TSH and
IGF-I.
RESULTS
DARPP-32 Is Expressed in Thyroid Cells
In the course of examining mRNAs that were differen-
tially expressed between differentiated and undiffer-
entiated thyroid cells, we isolated by RT-PCR a cDNA
corresponding to DARPP-32, a protein that alterna-
tively inhibits PP1 or PKA in dopaminoceptive neurons
of specific brain regions. To confirm the unexpected
observation that this gene is also expressed in thyroid,
we performed Northern blots using total RNA ex-
tracted from the thyroid cell line FRTL-5, unrelated
Rat1 fibroblasts, and fetal lung tissue using a rat
DARPP-32 cDNA as a probe. The results (Fig. 1A)
confirmed that DARPP-32 was expressed in the thy-
roid cell line FRTL-5, but not in unrelated Rat1 fibro-
blasts or fetal lung tissue. Similar results were ob-
served using the PC Cl3 thyroid cell line (data not
shown). To confirm that the gene was expressed in
primary thyroid tissue, we made Western blots using a
specific anti-DARPP-32 antibody and protein extracts
from brain and thyroid tissue. The results confirmed
that DARPP-32 is expressed in both thyroid and brain
as well as the PC Cl3 thyroid cell line (Fig. 1B). Actin
was used as a loading control. The high DARPP-32
expression levels found in cultured cells, as compared
with the primary tissue, could be attributed to many
reasons. For example, expression in the tissue could
be restricted to some cells in certain follicles as re-
ported for other thyroid proteins such as human apical
iodide transporter (7) or could be due to natural neg-
ative regulators present in the whole animal and ab-
sent in the cultured cells.
Although in neurons DARPP-32 is located in the
soluble fraction of the cytoplasm, in the parathyroid
DARPP-32 was found in the membrane fraction
where its target, PP1, is devoted to specific sub-
strates (8). To understand whether in thyroid cells
DARPP-32 is restricted to the membrane or soluble
fractions, we fractionated cell extracts from the PC
Cl3 thyroid cell line. Western blotting (Fig. 1C) re-
Fig. 1. DARPP-32 Is Expressed in Thyroid Cells and Is Cy-
toplasmic
A, Northern blot of RNA derived from thyroid cells (FRTL-
5), Rat1 fibroblasts, or rat fetal lung tissue (FL) as indicated
using a DARPP-32 cDNA probe. B, Western blot of brain,
thyroid tissue, and the thyroid cell line PC Cl3 using specific
anti-DARPP-32 antibody. C, Western blot of fractionated PC
Cl3 thyroid cells using anti-DARPP-32 antibody. WCE,
Whole-cell extract; CE, cytoplasmic extract; NE, nuclear ex-
tract; M, membrane fraction.
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vealed that most of the protein was located in the
soluble cytoplasmic fraction as in neurons and was
absent from the membrane fraction in contrast to
parathyroid cells. The small amount observed in the
nuclear fraction is due to small amount of cytoplasm
associated with the nuclei (see also some actin)
when fractionated by the Dignam method. Further-
more, microscopic observation of the cells stained
with anti-DARPP-32 antibodies reveals that most of
the protein is cytoplasmic (see Fig. 4B) with the
background nuclear staining being also found in
cells where DARPP-32 is undetectable by Western.
DARPP-32 Expression Correlates with Thyroid
Differentiation
In our initial RT-PCR experiments we found
DARPP-32 highly expressed in normal, differenti-
ated thyroid cell lines whereas it was absent in the
nondifferentiated Ha-Ras and K-Ras-transformed
FRTL-5 thyroid cell lines (9), as well as in the undif-
ferentiated human thyroid tumoral cell line (FRO)
(10). It was also absent from the undifferentiated
thyroid-derived cell line FRT, which manifests the
polarized epithelial phenotype but does not express
any of the thyroid functional properties (11). North-
ern blotting using a DARPP-32 probe on total RNA
derived from these cell lines confirmed the absence
of DARPP-32 mRNA in the nondifferentiated thyroid
cell lines (Fig. 2A). The results revealed that
DARPP-32 mRNA levels were decreased in parallel
with the degree of undifferentiation. Compared with
the high levels of DARPP-32 mRNA found in nor-
mally growing differentiated FRTL-5 cells, the Ha-
ras transformed FRTL-5 cells had barely detectable
levels, and DARPP-32 mRNA was undetectable in
both the K-ras-transformed FRTL-5 cells (see be-
low) and in the FRT cell line. These results sug-
gested that when differentiation is compromised by
transformation, DARPP-32 mRNA expression is si-
lenced. Remarkably, DARPP-32 mRNA is also ab-
sent in the nontransformed, but undifferentiated,
FRT thyroid cell line, reinforcing the correlation be-
tween lack of DARPP-32 expression and lack of
differentiation. In agreement with this, Fig. 2B shows
that DARPP-32 protein levels were also undetect-
able in the FRT, the K-ras/FRTL-5, and the FRO
thyroid cell lines and were severely reduced in the
Ha-ras-transformed FRTL-5 cells compared with the
normal FRTL-5 or PC Cl3 thyroid cells. Recombinant
DARPP-32 expressed in bacteria was used as a
positive control.
Although lack of differentiation in the tumor-de-
rived FRO and Ras-transformed thyroid cell lines
correlates with suppression of DARPP-32 expres-
sion, loss of DARPP-32 expression could be a sec-
ondary event associated with transformation. Nev-
ertheless, the correlation between DARPP-32
silencing and transformation, together with the fact
that the nontransformed but undifferentiated thyroid
cell line FRT is devoid of DARPP-32 expression,
raised the possibility that DARPP-32 might play a
role in thyroid differentiation. To further confirm that
DARPP-32 expression correlates with differentiation
in nontransformed thyroid cells, DARPP-32 expres-
sion was compared between quiescent, undifferen-
tiated PC Cl3 cells cultivated for 8 d in 4H medium
and differentiated PC Cl3 cells grown in the pres-
ence of TSH and IGF-I in 6H medium. In 4H medium
cells are quiescent, proliferation is minimal, and final
differentiation markers (such as Tg and NIS) are not
expressed, whereas cells proliferating in 6H medium
do express final differentiation markers. Total pro-
tein extracts from cells cultivated in 4H or 6H me-
dium were subjected to Western blotting and the
results are shown in Fig. 2C. Untransformed, quies-
cent thyroid cells cultivated in 4H medium and not
expressing differentiation markers show greatly re-
duced DARPP-32 protein levels compared with dif-
ferentiated thyroid cells growing in 6H medium (5- to
8-fold). Thus again, DARPP-32 expression levels
correlate with differentiation, suggesting that a pre-
Fig. 2. Thyroid Differentiation Directly Correlates with DARPP-32 Expression
A, Northern blot of RNA derived from undifferentiated (FRT), ras-transformed (K-ras, Ha-ras), or normal differentiated (Control)
FRTL-5 thyroid cells. B and C, Western blots of extracts from the indicated cell lines using a specific anti-DARPP-32 antibody.
Recombinant bacterially produced DARPP-32 was used as a positive control. C, Untransformed undifferentiated PC Cl3 thyroid
cells cultivated in 4H medium show reduced DARPP-32 protein levels as compared with differentiated thyroid cells growing in
6H medium.
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cise control of its activity may be required for proper
function and differentiation of thyroid cells. The ex-
tent of induction of DARPP-32 expression in 6H
medium varied between different experiments and
reflected differences in the degree of confluence at
the onset of starvation in 4H medium (data not
shown): slightly higher confluence at the onset of
starvation results in leaky expression of differentia-
tion markers, such as NIS, Tg, and DARPP-32, that
partially masks the induction by 6H medium. This
observation again emphasizes the parallel previ-
ously established between DARPP-32 levels and
expression of differentiation markers. Furthermore,
DARPP-32 mRNA or protein levels in cells cultivated
in 4H medium are low but detectable and at least 20
times higher than in Ha-Ras-transformed cells
where DARPP-32 is hardly detectable (data not
shown).
DARPP-32 Is Required to Maintain Thyroid Cell
Differentiation
Our results show that TSH and IGF-I stimulate
DARPP-32 expression in thyroid and that DARPP-32
expression strongly correlates with differentiation,
raising the possibility that DARPP-32 plays a role in
TSH and IGF-I-mediated thyrocyte differentiation. We
used siRNA to deplete differentiated thyrocytes of
DARPP-32 and asked whether the levels of the differ-
entiation markers were affected. A modified pSuper
vector expressing green fluorescent protein (GFP) and
either a DARPP-32-specific siRNA (pSGD), or a control
luciferase-specific siRNA (pSGL), were transfected
into PC Cl3 thyroid cells. Expression of DARPP-32, Tg,
and NIS was examined by immunofluorescence (data
not shown). The results indicated that DARPP-32 and
Tg expression were significantly reduced in the GFP-
positive cells transfected with the pSGD vector and
unaffected in control cells transfected with the vector
pSGL (see confocal photographs in Fig. 4). This was
confirmed by Western blotting of total protein extracts
of cells transfected with either interference vector as
described above using anti-NIS antibodies to monitor
differentiation. The results are presented in Fig. 3A.
Actin was used as a loading control whereas the ex-
pression of GFP reflects the efficacy of transfection.
Compared with the levels in the pSGL control-trans-
fected cells, DARPP-32 expression was reduced in
pSGD-transfected cells (DARPP-32 silenced) to ap-
proximately 30% of the control levels. Importantly, NIS
levels in the pSGD (DARPP-32 siRNA)-transfected
cells were 20% compared with the control pSGL-
transfected cells. Note that any reduction in
DARPP-32 expression will only occur in those cells
that are transfected and GFP positive. The efficiency
of transfection was similar in the DARPP-32 or Luc-
control siRNA-transfected cells as shown by the ex-
pression levels of the GFP protein as well as by mi-
croscopy (data not shown). Note also that the slight
increase in the GFP signal observed in the pSGD-
transfected cells arises in part due to a marginal in-
creased loading of this track as evidenced by a slightly
increased actin signal.
Expression of thyroid final differentiation markers
such as Tg or NIS is dependent on the transcription
factor Pax8. We examined whether Pax8 levels were
affected by the interference with DARPP-32 expres-
sion. Significantly, Western blotting using anti-Pax8
antibodies (Fig. 3B) indicated that on depletion of
DARPP-32, Pax8 protein levels were also reduced to
20–30% of the control levels. The results are consis-
tent with a model in which DARPP-32 depletion results
in Pax8 depletion and consequent loss of the final
differentiation markers Tg and NIS.
The results obtained using the pSuper-derived vec-
tors were confirmed using DARPP-32-specific siRNA.
Importantly, the efficacy of transfection using siRNA
was much higher than with the pSuper-derived vec-
tors and, compared with cells transfected with a non-
silencing siRNA control, by 24 h post transfection vir-
tually all DARPP-32 was eliminated from the cells as
determined by Western blotting (Fig. 4A). DARPP-32
levels remained very low 3 d after transfection but by
d 7 normal levels were recovered. We also monitored
several differentiation markers by Western. Strikingly,
depletion of DARPP-32 led to decreased levels of
TTF1, as well as Tg and NIS, and the levels of these
factors also recovered over time in parallel with
DARPP-32. Actin was used as a loading control. Im-
munofluorescence assays using anti-DARPP-32 and
anti-Tg together with confocal imaging confirmed the
results of the Western analysis. Whereas both
DARPP-32 and Tg were expressed robustly in control
cells, siRNA-mediated depletion of DARPP-32 led to a
Fig. 3. Specific Silencing of DARPP-32 by siRNA Causes
Lack of Expression of the Differentiation Markers NIS and
Pax8
Western blots using extracts from the following: control PC
Cl3 cells transfected with specific vectors to express the RNA
interference for Luc or DARPP-32: pSuper-GFP-Luc (Luc), or
with pSuper-GFP-DARPP-32 (DARPP-32); extracts from un-
differentiated, quiescent PC Cl3 cells are shown as a negative
control on Panel A. A, Specific depletion of the differentiation
marker NIS when DARPP-32 is depleted. B, Specific deple-
tion of Pax8 in cells transfected with the siRNA specific for
DARPP-32.
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dramatic reduction in both DARPP-32 and Tg expres-
sion within 1 d, the levels of both proteins recovering
over time. Note that by d 2 some cells expressing
DARPP-32 were already visible and these cells also
expressed Tg with the proportion of cells expressing
both markers increased with time. Thus, the results
Fig. 4. DARPP-32 Depletion by siRNA Interference Causes Lack of Differentiation in Thyroid Cells
A, TTF1, Tg, and NIS are specifically depleted by the DARPP-32 siRNA. Western blot of total protein extracts from cells
transfected with the Control siRNA (C) or the anti-DARPP-32-specific siRNA and collected on d 1–7. Control extracts correspond
to d 1. B, Confocal images of cells transfected with the siRNAs Control or DARPP-32 specific. In each picture the DAPI staining
shows total number of cells in the field: green is anti-DARPP-32 staining, and red is anti-Tg staining. Cells transfected with the
control siRNA show normal levels of both DARPP-32 and Tg. DARPP-32 depleted cells collected from d 1–5 show the lack of both
DARPP-32 and Tg and progressive recovery of both by d 5. The arrows on d 2 mark cells with a parallel recovery of both
DARPP-32 and Tg expression. DAPI, 4,6-Diamidino-2-phenylindole.
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obtained using both the pSuper and siRNA are con-
sistent with DARPP-32 playing a key role in the main-
tenance of differentiation.
Reintroduction of DARPP-32 into Ras-
Transformed Cells Overcomes Their Inability to
Activate the Tg and TPO Promoters
Upon DARPP-32 depletion, thyroid cells lose ex-
pression of differentiation markers such as Tg, sug-
gesting that DARPP-32 is required for full thyroid
cell differentiation. If DARPP-32 is required for Tg
expression, then reintroduction of DARPP-32 in
Ras-transformed thyroid cells that are devoid of
DARPP-32 and Tg expression should enable them
to reactivate the Tg promoter. Ha-ras-transformed
cells were transiently transfected with the expres-
sion vector pEGFP-DARPP-32 and the fusion Tg
promoter-luciferase reporter to quantify promoter
activity (Fig. 5A). Consistent with previous reports
(9) ectopic expression of TTF1 in these cells was not
sufficient to activate the Tg promoter. However, ec-
topic expression of DARPP-32 resulted in activation
of the Tg promoter (see a 2.5-fold increase in lucif-
erase activity) consistent with DARPP-32 playing a
role in differentiation, and TTF1 coexpression re-
sulted in a marginal increase over the induction
obtained by expression of DARPP-32. Previous
studies (12) suggested that the equilibrium between
kinases and phosphatases necessary to maintain
TTF1 active is broken in Ha-ras-transformed thyroid
cells as revealed by an altered phosphorylation pat-
tern of TTF1. Therefore, exogenous DARPP-32 ex-
pression may increase the TTF1 levels and rescue
the kinases/phosphatases equilibrium in Ha-ras-
transformed cells rendering enough active TTF1 to
promote Tg promoter activity. Figure 5B shows sim-
ilar results obtained with the TPO promoter, another
classical differentiation marker. TPO promoter is si-
lent in Ha-ras-transformed thyrocytes, and we show
that after reexpressing DARPP-32 its activity in-
creases 2-fold similarly to the Tg promoter. Coex-
pression of TTF1 and DARPP-32 only results in a
marginal increase over that produced by DARPP-32
alone. These results further confirm that DARPP-32
plays a crucial role in signal transduction pathways
leading to thyroid differentiation.
TSH and IGF-I Independently Up-Regulate
DARPP-32 Levels
Because TSH and IGF-I are the most physiologically
relevant stimuli for thyroid function and we have
shown that DARPP-32 is required for thyroid differen-
tiation, we wished to study whether these stimuli tar-
geted DARPP-32 expression. Undifferentiated PC Cl3
cells cultivated in 4H medium for 8 d were treated with
TSH and/or IGF-I for 24 h. Western blotting of total
protein extracts (Fig. 6) revealed that TSH induced
DARPP-32 expression 5- to 8-fold above basal levels
after 24 h treatment. Similar results were obtained with
IGF-I. Simultaneous addition of TSH and IGF-I resulted
in a similar induction to that observed using either TSH
or IGF-I. Actin was used as a loading control. Quanti-
fication of the results obtained in three independent
experiments as is shown at the bottom graphics dem-
onstrates that the extent of induction is similar with
either or both stimuli.
Thus both TSH or IGF-I independently exert maxi-
mal DARPP-32 induction, and DARPP-32 is a com-
mon target for multiple signaling pathways involved in
thyroid function or differentiation.
Fig. 5. DARPP-32 Reintroduction in H-ras-Transformed Cells Overcomes Their Inability to Activate the Tg and TPO Promoters
Ha-ras/FRTL-5 cells were transfected with the Tg (A) or TPO (B) promoter fused to the luciferase reporter and/or the TTF1
expression vector pTTF1 and/or pEGFP-N1 or the DARPP-32 expression construct pEGFP-DARPP-32. Relative luciferase activity
normalized with Renilla was measured 72 h after transfection. Promoter activity is expressed as fold induction over basal level
(1) of the cells transfected with either the pTg (A) or pTPO (B) construct alone. The results represent the mean  SD of three
independent experiments. The bottom panels show the expression levels of ectopically expressed DARPP-32 in one represen-
tative experiment. EGFP, Enhanced GFP.
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The PKA and PI3K Pathways Are Required for
DARPP-32 Induction by TSH and IGF-I,
Respectively
To unravel critical components of the signaling path-
ways from TSH or IGF-I to DARPP-32, we asked
whether specific protein kinase inhibitors could affect
the TSH- or IGF-I-mediated induction of DARPP-32
expression. We first used H89, an inhibitor of PKA. PC
Cl3 cells cultivated in 4H medium for 8 d were pre-
treated with 10 M H89 for a minimum of 30 min before
addition of thyrotropin or IGF-I for 24 h. TSH and IGF-I
in the absence of the inhibitor exerted an induction
similar to that shown in the previous figures (data not
shown). In contrast, H89 treatment abolished both
TSH and IGF-I-mediated induction of DARPP-32 (Fig.
7A). Treatment with H89 alone did not modify basal
levels of DARPP-32 after 30 min treatment (data not
shown) or after 24 h (compare first and last lanes).
The PI3K pathway plays an important role in thyroid
cell signal transduction downstream of IGF-I (13), and
it has been reported to cross talk with TSH signaling
(14) (15). To determine whether PI3K was important for
DARPP-32 regulation, PC Cl3 cells cultivated in 4H
medium were treated with the PI3K inhibitor
LY294002, as described previously for H89. Again, in
the absence of the inhibitor, DARPP-32 was induced
by IGF-I and TSH as expected (data not shown). Strik-
ingly, LY294002 treatment depleted DARPP-32 after
24 h (Fig. 7B; compare first and last lanes), suggesting
that PI3K signaling is required to maintain DARPP-32
expression. In the presence of LY294002, IGF-I was
inactive, neither leading to an induction of DARPP-32
expression nor preventing the loss of basal expres-
sion. By contrast, TSH restored the basal level of
DARPP-32 expression, suggesting that the ability of
TSH to induce DARPP-32 was not inhibited by
LY294002. Taken together, the results suggest that
TSH may use the PKA pathway to induce DARPP-32,
whereas the effects of IGF-I would require PI3K sig-
naling. Note that because H89 has also been shown to
inhibit the PI3K/PDK1 substrate S6K1with the same or
greater potency (16), the failure of IGF-I to induce
DARPP-32 expression in the presence of H89 could
be due to inhibition of S6K1 rather than PKA, or to a
cross talk between these pathways (17). The PI3K
inhibitor LY294002, but not H89, blocks basal expres-
sion of DARPP-32, suggesting that the PI3K-depen-
dent pathway required for DARPP-32 basal expres-
sion is p70S6K-independent.
TSH and IGF-I Promote DARPP-32
Phosphorylation at Thr34
So far we could block differentiation by depleting
DARPP-32 in thyroid cells and conversely promote
differentiation by reintroduction of DARPP-32 in cells
poorly expressing the protein. Moreover, TSH and
IGF-I, the most physiologically relevant stimuli for thy-
roid function, induced DARPP-32 accumulation.
DARPP-32 function depends on its phosphorylation
status: when phosphorylated on Thr75 DARPP-32 in-
hibits PKA while phosphorylated on Thr34 inhibits
PP1, these phosphorylation events being mutually ex-
clusive (i.e. phospho Thr34 DARPP-32 cannot be
Fig. 6. TSH and IGF Independently Up-Regulate DARPP-32
Protein Levels
Western blot of total protein extracts from PC Cl3 cells
cultivated for 9 d on 4H medium and supplemented () or not
() with TSH, IGF-I, or both during the last 24 h. The data
represent the mean  SD of three independent experiments.
Fig. 7. Signaling from TSH and IGF-I to DARPP-32 Involves
Both PKA and PI3K
Western blots of total protein extracts. A, Treatment of PC
Cl3 cells with H89, an inhibitor of PKA and S6K inhibits
DARPP-32 induction by TSH and by IGF-I. B, LY294002, an
inhibitor of PI3K, prevents IGF-I induction and depletes basal
levels of DARPP-32. LY, LY294002.
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phosphorylated at Thr75 and vice versa). We were
unable to detect P-Thr75 DARPP-32 in our cells but
could easily detect the P-Thr34 form that inhibits PP1
(Fig. 8). Furthermore, we observed that both TSH and
IGF-I independently induced phosphorylation of
DARPP-32 at Thr34 (Fig. 8A). P-Thr34-DARPP-32 in-
duction by TSH peaks at 12 h of treatment (5- to
6-fold) and by 24 h is approximately 3-fold relative to
actin levels. IGF-I induction of P-Thr34-DARPP-32
was also 3- to 4-fold at 12 h and still increased up to
6-fold at 24 h (Fig. 8B). TSH induction of P-Thr34 was
mediated via PKA because it was prevented by its
inhibitor H89 (Fig. 9A). Induction of P-Thr34 at 12 h by
IGF-I was unaffected by H89, but the phosphorylation
of DARPP-32 was transient with no signal being ap-
parent by 24 h, in contrast to cells not treated with the
inhibitor (see Fig. 8B). The PI3K inhibitor LY294002 did
not affect TSH-induced phosphorylation of DARPP-32
(Fig. 9B). Any effect of LY294002 on IGF-I-induced
phosphorylation of DARPP-32 was difficult to assess
given our observation that this inhibitor abolishes
basal and IGF-I induced DARPP-32 expression (see
Fig. 7B). We were consequently unable to detect P-
Thr34 DARPP-32 in the presence of LY294002 alone
or with IGF-I. In the absence of any inhibitor, IGF-I and
TSH induced DARPP-32 phosphorylation as expected
(data not shown). These data suggest that both TSH
and IGF-I induce DARPP-32 expression and, through
phosphorylation of DARPP-32 at Thr34, convert it into
a potent inhibitor of PP1.
DISCUSSION
DARPP-32 is a bifunctional molecule the expression of
which was once believed to be restricted to dopami-
noceptive neurons in discrete regions of the brain
where its function has been extensively studied. Its
importance in neurons is highlighted by the fact that
more than 10 different signaling pathways alter this
molecule, and its function has been implicated in a
number of diseases including Parkinson, Huntington,
schizophrenia, hyperactivity and attention deficit syn-
drome, and long-term depression (18). Neuronal
DARPP-32 has been shown to mediate the effects of
dopamine, cocaine, serotonin, fluoxetine (Prozac), and
caffeine and a range of other molecules. Here we
report the finding that DARPP-32 is expressed in nor-
mal thyroid gland and thyroid cell lines. More impor-
tantly, we provide four lines of evidence that
DARPP-32 is essential for the maintenance of thyroid
cell differentiation. First, thyroid cells kept undifferen-
tiated in 4H medium posses low basal DARPP-32
levels, which are inducible by TSH or IGF-I as are other
differentiation markers. TSH and IGF-I induction of
thyroid differentiation has been widely documented
before (19, 20, 21, 22) although this is the first report of
DARPP-32 expression in these cells. Second, there is
a good correlation between DARPP-32 levels and the
degree of differentiation. Thus, DARPP-32 is absent in
Fig. 8. TSH and IGF-I Promote DARPP-32 Phosphorylation
at Thr34
Western blot of total protein extracts from PC Cl3 cells
cultivated for 9 d on 4H medium and supplemented () or not
() with TSH, IGF-I, or both during the last 12–24 h. The data
represent the mean  SD of three independent experiments.
Fig. 9. TSH-Dependent Thr34 Phosphorylation of
DARPP-32 Is Mediated by PKA and the IGF-I-Dependent
Phosphorylation Occurs via PI3K
Western blots of total protein extracts. A, Treatment of PC
Cl3 cells with H89 inhibits TSH-mediated, but not IGF-I me-
diated, phosphorylation of DARPP-32 at Thr34. B, LY294002,
an inhibitor of PI3K, prevents IGF-I mediated phosphorylation
of DARPP-32 at Thr34 but not the TSH-dependent phosphor-
ylation. The data represent the mean  SD of three indepen-
dent experiments.
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tumoral (FRO) or Ras-transformed thyroid cell lines
and in the undifferentiated but nontransformed thyroid
cell line FRT. Third, siRNA-mediated silencing of
DARPP-32 leads to a dramatic inhibition of expression
of the key thyroid transcription factors, Pax8 and
TTF1, and probably as a consequence of thyroid-spe-
cific differentiation markers such as Tg and NIS.
Fourth, reintroduction of DARPP-32 in Ha-ras-trans-
formed thyroid cells enables them to activate the oth-
erwise silent Tg promoter.
TSH and IGF-I cooperate to promote thyrocyte pro-
liferation and function (3, 23). We demonstrate that
both TSH and IGF-I induce total DARPP-32 accumu-
lation and also its phosphorylation at Thr34, thereby
converting it into a potent inhibitor of PP1. Phosphor-
ylation of DARPP-32 on Thr34 prevents its phosphor-
ylation at Thr75, a form of the protein that inhibits PKA.
The lack of P-Thr75 DARPP-32 in thyroid cells possi-
bly reflects the importance of an active PKA pathway
for these cells to survive or differentiate. Moreover, the
mechanisms by which TSH and IGF-I induce accumu-
lation of total DARPP-32 are different: TSH induction
occurs through mRNA accumulation, whereas IGF-I
induction appears to be posttranscriptional (our manu-
script in preparation).
Conversely, we have also tested the hypothesis that
DARPP-32 may increase TSH and IGF-I receptor lev-
els giving rise to a positive feedback loop involving
TSG/IGF-I, their receptors, and DARPP-32. We de-
tected a significant decrease in IGF-I R but not in TSH
receptor (TSH-R) levels after silencing DARPP-32 (our
unpublished observations). However, under our con-
ditions the quality of the TSH-R antibody does not
allow us to discard a hypothetical decrease of the
TSH-R in cells transfected with DARPP-32-specific
siRNA. Nevertheless it is generally accepted that fail-
ures in signaling intermediates from the TSH-R are
responsible for the lack of differentiation. Accordingly,
in a recent study by Di Lauro and associates (24),
Ha-ras-transformed thyrocytes are shown to differen-
tiate in response to TSH only when Ras is expressed
at low dose but not at high dose. It would therefore
be particularly interesting to determine whether
DARPP-32 expression levels parallels Ras dose in
their system.
Proliferation of thyroid cells, on the other hand, does
not seem to be controlled by DARPP-32 levels. We did
not observe an effect of DARPP-32 on thyroid cell
proliferation neither when we depleted it from normally
growing thyroid cells nor on its reintroduction into
Ha-ras-transformed cells. Moreover, thyroid cells with
proliferation rates varying from the very high (Ras-
transformed and tumoral) to the nonproliferative thy-
roid cells cultivated in 4H medium have undetectable
or very low DARPP-32 levels.
Malignant transformation is often characterized by
dedifferentiation. Consistent with this, Ras-mediated
transformation of thyroid cells or naturally occurring
thyroid tumor cell lines exhibit a loss of differentiation
markers such as Tg and NIS. Our results presented
here indicate that DARPP-32 expression is also lost in
transformed and tumoral thyroid cells and may repre-
sent a useful marker for the progression of thyroid
carcinoma. In contrast, in gastric cancers (25) and
some common adenocarcinomas DARPP-32 is over-
expressed (26) compared with their normal untrans-
formed parental cell types. Future research will un-
cover any potential role of DARPP-32 in cancer
progression. Nevertheless, the evidence suggests that
DARPP-32 may lie at the nexus of multiple signaling
pathways that modulate or maintain the differentiation
state of a given cell type.
IGF-I-dependent induction of DARPP-32 in thyroid
cells, mediated by activation of PI3K, is reminiscent of
the PI3K-dependent induction of DARPP-32 in neu-
rons by brain-derived neurotrophic factor acting
through its tyrosine kinase receptor (27), and it may be
a general theme that receptor tyrosine kinases in other
cell types may use this signaling pathway to regulate
DARPP-32 expression. Indeed, although we have fo-
cused here on the effects of TSH and IGF-I on thyroid,
TSH and IGF-I receptors are also expressed in neu-
rons (28, 29), and, potentially, neuronal DARPP-32
levels could be subjected to similar regulation. This
may be particularly important for understanding the
link between metabolic and psychological effects of
drugs targeting neuronal function. Thus, DARPP-32
may be viewed as a third messenger of hormones,
growth factors and neurotransmitter action.
In thyroid, the role of DARPP-32 appears to be in
mediating the effects of TSH and IGF-I in differentia-
tion. Thus, in the absence of TSH or IGF-I, or on
depletion of DARPP-32, we observe a loss of expres-
sion of the thyroid differentiation markers Tg and NIS.
Iodination of Tg residues is essential for the differen-
tiated function of the thyrocyte and depends on func-
tional NIS at the membrane. The expression levels of
NIS at the membrane directly correlate with iodide
uptake both in thyroid and nonthyroid cells (30, 31).
We have examined NIS expression at the membrane
after DARPP-32 silencing in thyrocytes, and we ob-
serve a direct correlation between the levels of
DARPP-32 and the membrane population of NIS (data
not shown). The expression of these final differentia-
tion markers depends on the activity of “teams” of
cell-specific and ubiquitous transcription factors (1),
the most important among them being TTF1, TTF2,
and Pax8. Pax8 has been previously shown to be
required for differentiation of competent endoderm
into follicular thyroid cells producing thyroid hormones
(32), and our results suggest that DARPP-32 is nec-
essary to maintain the Pax8 expression/activity re-
quired for differentiation promoted by TSH and IGF-I.
We also show that DARPP-32 expression is necessary
to maintain adequate levels of active TTF1. Ha-ras-
transformed thyroid cells contain low levels of inap-
propriately phosphorylated, and therefore inactive,
TTF1 (12). Reintroduction of DARPP-32 capable of
inhibiting PP1 might be therefore necessary for correct
TTF1 and Pax8 phosphorylation and activity and
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therefore reexpression of DARPP-32 in Ha-ras-trans-
formed thyrocytes results in reactivation of the Tg and
TPO promoter. As far as we are aware, this is the first
demonstration that DARPP-32 as an integrator of sig-
nal transduction pathways plays a key role in differen-
tiation. Our data could be particularly relevant in adi-
pocytes where it has been reported that DARPP-32
levels dramatically increase upon 3T3-L1 differentia-
tion toward adipocytes (33).
We suggest for thyroid cells the model depicted in
Fig. 10. In this model, the principal role of DARPP-32
(Fig. 10B) is to inhibit the activity of PP1 and thereby
stabilize the TSH and IGF-I-induced phosphorylation
and activation of key transcription factors. Basal levels
of DARPP-32 are required to amplify immediately the
TSH and IGF-I effects. TSH and IGF-I stimulation (via
PKA and PI3K, respectively) will induce phosphoryla-
tions affecting the levels and activity of transcription
factors (Pax8, TTF1), which will turn on transcription of
differentiation markers (Tg, NIS). TSH/IGF-I-induced
accumulation and phosphorylation of DARPP-32 at
Thr34 turns off the general phosphatase PP1 main-
taining high levels of phosphorylated transcription fac-
tors, which prolongs the initial phosphorylation events
allowing accumulation of differentiation markers. The
effects of TSH and IGF-I would then be further ampli-
fied by their ability to induce DARPP-32 expression.
By contrast, in cells lacking DARPP-32 expression
(Fig. 10A), unrestricted PP1 activity will reverse any
TSH- and IGF-I-induced phosphorylation of TTF1 and
Pax8. Any effect of TSH and IGF-I signaling would
therefore be transient and insufficient to support the
accumulation of active Pax8 and TTF1, and full differ-
entiation would not be possible.
MATERIALS AND METHODS
Cell Culture
Cell lines used in this work were: rat thyroid follicular FRTL-5
(34) (ATCC CRL 8305; American Type Culture Collection,
Manassas, VA), Ha-ras- and K-ras-transformed FRTL-5 cells
(35), rat PC Cl3 (36), rat FRT (11), and human FRO (10). The
cells were cultured in Coon’s modified Ham’s F-12 medium
supplemented with 5% donor calf serum, glutamine, antibi-
otics, and a six-hormone mixture (1 nM TSH, 10 g/ml insulin,
Fig. 10. A Model for the Role of DARPP-32 in Thyroid
In thyroid cells, phosphorylation of transcription factors (P-TFs) such as Pax8 and TTF1 in response to TSH and IGF-I signaling
is required for their activation and consequently for their ability to activate transcription (Tx) of differentiation specific genes. In
tumoral (FRO), Ras-transformed, or undifferentiated thyroid cells (FRT) lacking DARPP-32 (panel A), the ability of TSH and IGF-I
to promote phosphorylation of transcription factors is largely reversed by the action of PP1. Consequently, the cells are
undifferentiated. By contrast, in differentiated thyroid cells expressing DARPP-32 (panel B), the presence of active DARPP-32
(phosphorylated at Thr34) will lead to inhibition of PP1 and consequently IGF-I and TSH signaling will lead to the stable
phosphorylation and activation of transcription factors that promote the expression of differentiation genes (Tg, NIS, etc.). In
quiescent thyroid cells the low level of DARPP-32 expression observed should allow IGF-I and TSH to initiate the differentiation
program, whereas the ability of IGF-I and TSH to increase DARPP-32 expression and activity will then amplify the prodifferen-
tiation signals.
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10 ng/ml somatostatin 10 g/ml transferrin, 10 nM hydrocor-
tisone, and 10 ng/ml glycyl-L-histidyl-L-lysine acetate). The
effect of TSH and IGF-I was studied by starving nearly con-
fluent cells of TSH, IGF-I, and serum (0.1%) for 8–9 d (4H
medium). TSH (1 nM) and/or IGF-I (100 ng/ml) were added for
24 h. Inhibitors (when used) were added to the cells 30 min
before addition of TSH or IGF-I at the concentration of 10 mM
in both cases (both from Calbiochem, La Jolla, CA) and
maintained for 24 h. Appropriated controls were established
(i.e. 4H  inhibitor for 30 min, 4H  inhibitor for 24 h, 4H 
inhibitor  TSH). Tissue culture media and bovine TSH were
purchased from Sigma Chemical Co. (St. Louis, MO). IGF-I
was obtained from Preprotech (Rocky Hill, NJ). Donor calf
serum was purchased from Life Technologies, Inc. (Gaithers-
burg, MD). The medium was changed every 2 d.
RNA Extraction and Northern Blot Analysis
Total RNA was isolated by the guanidinium-thiocyanate-phe-
nol method (37) from the indicated cell lines or tissues after
the indicated treatments. Total RNA (20 g) was separated in
1% agarose gels containing 2.2 M formaldehyde. RNA was
blotted onto Nytran filters (Schleicher & Schuell, Keene, NH)
as suggested by the manufacturer. Methylene blue staining
of the blots revealed the integrity of the RNA and the pres-
ence of equal amounts in each lane. Hybridization and wash-
ing were carried out with a rat cDNA DARPP-32-specific
probe kindly donated by Dr. Greengard (Laboratory of Mo-
lecular and Cellular Neuroscience, Rockefeller University,
New York, NY) and labeled by Random oligo priming.
Protein Extraction, Western Blot, and Immunodetection
Total protein extracts were obtained by scraping the cells in
RIPA buffer. Fractionated (cytoplasmic, nuclear) protein ex-
tracts from the indicated cell lines were obtained as de-
scribed in Ref. 38; membrane fractions were isolated as
described in Ref. 39. Protein extracts (20 g) were separated
in 6–12%SDS-PAGE gels and inmunodetected after Western
blotting. Antitotal DARPP-32 and anti-P Threo 34-DARPP32
antibodies were kindly donated by Dr. Greengard, and the
other antibodies were from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA). Secondary antibodies were horseradish
peroxidase conjugated and detected by autoradiography.
Equal protein loading was first monitored by Bradford assays
and after transfer by detection of the nonregulated proteins,
cdk5 or -actin.
Constructs
A cytomegalovirus-GFP-PolyA fragment digested with AseI/
MluI out of the pEGFP-C3 vector (CLONTECH Laboratories,
Inc., Palo Alto, CA) previously deleted of the multiple cloning
site by BamHI/BglII digestion and religation was cloned into
the SmaI site of pSuper and pSuper-Luc plasmids (Oligo-
engine) generating the intermediate plasmid pSuperGFP
(pSG) and the final construct pSuperGFPLuc (pSGL). The
following oligonucleotide sequences were designed and pur-
chased from QIAGEN (UK) to synthesize the specific
DARPP-32 RNAi: Oligo1: 5-GAT CCC CAA GTC GAAGAG
ACC CAA CCT TCA AGA GAG GTT GGG TCT CTT CGA CTT
TTT TTG GAA A-3 and oligo 2: 5-AGC TTT TCC AAA AAA
AGT CGA AGA GAC CCA ACC TCT CTT GAA GGT TGG GTC
TCT TCG ACT TGG G-3; the oligos were annealed and
phosphorylated using polynucleotide kinase from Promega
Corp. (Madison, WI) and introduced into the BglII/HindIII sites
of pSG, generating the final construct pSuperGFP-DARPP
(pSGD).
Ha-ras-transformed FRTL-5 cells were transfected with:
pTg as described in Ref. 40 or pTPO promoter as described
previously (9); pTTF1 (expression vector for TTF1) as de-
scribed in (41); and/or pEGFP-DARPP-32, which was con-
structed by cloning DARPP-32 into the BglII/ EcoRI sites of
the pEGFP N1 vector (CLONTECH). pRL-CMV, a vector con-
taining cDNA encoding Renilla (Promega), was cotransfected
to monitor transfection efficiency. DARPP-32 siRNA oligonu-
cleotides with sequences r(CCCCUGCCUUGCUGUUCCG)
d(TT) and r(CGGAACAGCAAGGCAGGGG)d(TT) and control
siRNA oligonucleotides with sequences r(UUCUCCGAACG-
UGUCACGU)d(TT) and r(ACGUGACACGUUCGGAGAA)d(TT)
were purchased from QIAGEN (Chatsworth, CA) and an-
nealed according to manufacturer’s instructions.
Transfection
PC Cl3 cells were transfected while plated using Fugene
(Roche Molecular Biochemicals, Indianapolis, IN) and follow-
ing manufacturer suggestions. For microscopy and Western
analysis of the siRNA, cells were transfected on cover slips at
104 cells per well in 24-well dishes. In every experiment 12
wells were transfected with the control construct pSGL con-
taining the sequence to synthesize the luciferase siRNA and
12 wells were transfected with the construct pSGD contain-
ing the sequence for DARPP-32 siRNA and above described.
Maximum GFP expression was reached 5–6 d after transfec-
tion and monitored directly using the green filter under the
fluorescence microscope. Alternatively, siRNA oligoribonu-
cleotides, either control or DARPP-32 specific, were trans-
fected into cells (plated at 104 cells per well the previous day)
using Oligofectamine (Invitrogen, San Diego, CA) and follow-
ing manufacturer’s instructions. The medium was changed
24 h later and every 2 d afterward. Cells transfected directly
with the siRNAs were collected on d 1–7 after transfection to
analyze the expression of DARPP-32, Tg, NIS, etc. by immu-
nofluorescence or Western blotting.
Transfection of Ha-ras cells to assay the ability of the Tg
promoter to direct luciferase transcription was also done
using Fugene Reagent. cDNAs transfected included pTg-
LUC, pRL-CMV, and either the pEGFP-DARPP-32 construct
or the pEGFP-N1 empty vector and/or pTTF1 (1 g each
except for the pRL-CMV that was 0.5 g).
Indirect Immunofluorescence
Cells in cover slips were washed three times and fixed in
Methanol at 20 C for 10 min; washed again and blocked
with PBS containing 5% donor calf serum and 0.05% Tween
for 1 h at room temperature, incubated with anti-DARPP-32
or anti-Tg antibody for 20 min at R/T, washed in PBS-Tween
three times for 5 min, incubated with the secondary antibody
Alexa 488 or Texas Red conjugated, respectively, washed
again three times with PBS-Tween and mounted on Vectash-
ield containing 4,6-diamidino-2-phenylindole (Vector Labo-
ratories, Inc., Burlingame, CA). Cells were observed under
epifluorescent (Axiophot; Carl Zeiss, Thornwood, NY) using
63 magnification on oil immersion objective or confocal
microscopy (Leica Corp., Deerfield, IL). Images were re-
corded in a Olympus DP70 camera (Olympus Corp., Lake
Success, NY) using DP70-BSW software.
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